Houston Matters

Houston Methodist Studying Effects of Emerging Immunotherapy Drug

A study underway at Methodist Hospital compares the effects of an immunotherapy drug to a chemotherapy drug on certain lung cancer development. Lung cancer is the second most common malignancy in the United States. We learn more about the study from its principal investigator, Dr. Eric Bernicker, Thoracic Medical Oncologist with the Houston Methodist Cancer Center.

A study underway at Methodist Hospital compares the effects of an immunotherapy drug to a chemotherapy drug on certain lung cancer development. Lung cancer is the second most common malignancy in the United States.

We learn more about the study from its principal investigator, Dr. Eric Bernicker, Thoracic Medical Oncologist with the Houston Methodist Cancer Center.

Share